3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
20
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Endometrial Neoplasms
2
Disease Progression
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
1
Glioma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Fulvestrant
2
vistusertib
1
proto-oncogene protein c-fes-fps
1
capivasertib
1
Transurethral Resection of Bladder
1
Hydroxychloroquine
1
Everolimus
1
Estrogens
1
Estradiol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Estrogen Receptor Positive Breast Cancer
×
capivasertib
×
Breast
×
Clear all
NCT01992952
2025-11-26
FAKTION
Velindre NHS Trust
Phase 1/2
Active not recruiting
149 enrolled